Objectives: Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii are becoming increasingly important nosocomial pathogens worldwide. To study the evolution of non-fermenters in a tertiary care hospital, we undertook a retrospective 10 year (1999 -2008) trend analysis of antimicrobial consumption and resistance in non-fermenters causing bacteraemia.
Introduction
Hospitals worldwide are continuing to face a crisis in the upsurge and dissemination of antimicrobial-resistant bacteria, particularly non-fermenters causing nosocomial infections. 1 The increasing prevalence of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii (MDRPA and MDRAB) organisms is alarming, as effective antimicrobial options are severely limited. 2 Antimicrobial resistance among bloodstream isolates is considered a significant problem worldwide, and inappropriate treatment results in increased mortality rates. 3 Although there is evidence of a causal link between antibiotic consumption and resistance, 4 it remains a complex issue. Other factors, such as inter-hospital transfer of resistance due to patient transfers, community contribution to resistance, structures of healthcare systems and infection control policies and practices, may also play a role in determining the prevalence of resistance in a hospital. Recently there has been a focus on antimicrobial consumption and resistance patterns to understand the local epidemiology in formulating hospital antibiotic policy. Although regional surveillance data on antimicrobial consumption and resistance trends among bacteria are needed to assess their evolution, these data are lacking from the Indian region. Information and data on trends in antibiotic prescriptions and resistance, although available from other parts of the world, 5 are urgently needed in this part of the world to fill this gap.
We present the first report on a 10 year trend analysis of antimicrobial consumption and the development of resistance among non-fermenters in a tertiary care hospital in Delhi, India.
Methods

Setting and timing
Sir Ganga Ram Hospital is a 650-bed, multi-specialty, tertiary care teaching hospital in Delhi, India. It is an active centre for liver, renal and bone marrow transplant surgeries. This hospital also serves as a referral hub for Delhi as well as the whole of India for super-specialty care. The study is a 10 year (1999-2008) retrospective trend analysis of antimicrobial consumption, resistance and their association in non-fermenters (P. aeruginosa and A. baumannii) causing bacteraemia in admitted patients [wards and intensive care units (ICUs)].
Antimicrobial testing
All the blood samples received were cultured by BacT/ALERT 3D (bioMér-ieux, Marcy l'Étoile, France). The isolates were identified by routine methods and antimicrobial susceptibility was determined by the Kirby Bauer disc diffusion method as per CLSI criteria. 6 Manual identification and susceptibility testing were upgraded in 2002 to an automated system using a Vitek identification and MIC testing system (bioMérieux). Non-fermenters were studied for the following antimicrobial groups as per the ATC classification using ABC calc software (available free online):
7 J01DD (third-generation cephalosporins; ceftazidime and ceftriaxone); J01CR03 and J01CR05 (b-lactam/inhibitor combinations; piperacillin/tazobactam and ticarcillin/clavulanate); J01MA (fluoroquinolones; ciprofloxacin and levofloxacin); J01GB (aminoglycosides; gentamicin and amikacin); and J01DH (carbapenems; imipenem and meropenem). Tigecycline and colistin were excluded from our trend study, as these were tested from 2008 onwards. Antibiotic resistance data were analysed using a FoxPro-based indigenously designed program until 2006; after that, customized software (Speedminer, Petaling Jaya, Malaysia) was used to extract the data from the hospital information system (Intersystems, Cambridge, MA, USA). Repeat isolates were excluded from the data if the same organism was grown from the same patient in a 15 day interval.
Antimicrobial consumption data
Ten years of antimicrobial consumption data were evaluated from the antibiotic purchasing data from the hospital information system. Hospital purchasing data were used as a proxy for consumption, assuming that the same amount was dispensed to the patients. 8 The amount of antimicrobial drug in grams was converted into the number of defined daily doses (DDDs)/100 bed-days using ABC calc.
Statistical analysis
Trend analysis of consumption and resistance for each antimicrobial was carried out using linear regression. The presence or absence of an association with resistance was tested using the Pearson correlation coefficient (r) using SPSS (version 17) (Chicago, IL, USA) software.
Results
Isolation
During the entire study period a total of 69 010 blood cultures were performed, with an increasing trend in the number of blood cultures performed; 4380 cultures per year in 2000 to 8608 cultures per year in 2008. A total of 15465 isolates (22% positivity rate) grew, of which 1525 isolates (771 isolates of P. aeruginosa and 754 isolates of A. baumannii) were nonfermenters. A. baumannii incidence rose more rapidly (9-fold) as compared with P. aeruginosa (6-fold) ( Table 1 ). There was also a remarkable emergence of non-fermenters causing bacteraemia, increasing from 4% (37 isolates) in 1999 to 28.6% (374 isolates) in 2008.
Antimicrobial consumption
There was a 2-fold increase in the rate of total antimicrobial consumption between 1999 and 2008. Table 1 shows that, in 2008, the b-lactam/inhibitor group was the major antimicrobial consumed of those included, constituting 19.2% of total use. This was followed by fluoroquinolones (15%), third-generation cephalosporins (11%), aminoglycosides (9%) and carbapenems (3.6%). Carbapenems and the antipseudomonal b-lactam/inhibitor combination piperacillin/tazobactam were introduced in our hospital formulary in 2002. Since then, the largest relative increase in consumption (10-fold) was observed for carbapenems, followed by a 4-fold increase in consumption of b-lactam/inhibitor combinations. Less substantial changes in the consumption of other antimicrobials were seen, as shown in Table 1 . We observed a significant increasing trend in fluoroquinolone consumption from 1999 to 2005, peaking at 91.9 DDDs/100 bed-days (r Table 1 shows a high rate of resistance in A. baumannii in 2008 to third-generation cephalosporins (88%), fluoroquinolones (86%), aminoglycosides (80%), b-lactam/inhibitor combinations (80%) and carbapenems (74%). A significant and dramatic increase in resistance to aminoglycosides, fluoroquinolones and carbapenems in A. baumannii was seen over the 10 years of this study. A significant but less dramatic increasing resistance trend was seen in P. aeruginosa to aminoglycosides. Likewise the resistance rates in P. aeruginosa to thirdgeneration cephalosporins, fluoroquinolones, aminoglycosides, b-lactam/inhibitor combinations and carbapenems were 42%, 65%, 65%, 44% and 55%, respectively, in 2008, which were lower compared with A. baumannii. Overall, Table 1 highlights that trends of increasing resistance were much stronger for A. baumannii compared with P. aeruginosa across all classes of antimicrobials. Colistin and tigecycline susceptibility tests were routinely performed from 2008 onwards. In 2008 colistin resistance was less than 1% in A. baumannii and P. aeruginosa, whereas tigecycline showed a high resistance rate of 70% in A. baumannii.
Antimicrobial resistance
Correlation
We observed a significant correlation between total antimicrobial use and the isolation rate of P. aeruginosa (r ¼0.838, P ¼ 0.003) and A. baumannii (r¼ 0.838, P ¼0.02) (Figure 1) . A significant but weak association was observed for carbapenem consumption and resistance in A. baumannii, whereas no association was observed for carbapenem consumption and resistance in P. aeruginosa (Table 2) . Similarly no association was seen between antimicrobial consumption and the development of resistance for other classes of drugs in our study.
Discussion
Non-fermenters are emerging as important opportunistic nosocomial pathogens in our institute. The increase in the incidence of non-fermenters was significantly associated with total antimicrobial consumption, indicating that there is selecting out of MDRAB and MDRPA under antimicrobial pressure. The increase may also be explained by the increasing number of blood cultures being performed over the years and thus an increase in the isolation rate. The increasing number of blood cultures drawn may also reflect periods of increasing antibiotic consumption, as shown by Lamoth et al. 9 Similar trends of increasing prevalence of nosocomial non-fermenters have been noted in other surveillance studies as well. 1, 10 Despite its importance, there is very little available information about hospital antimicrobial consumption in India. This may be because of a lack of systems that allow assessment of antibiotic consumption. During our 10 year analysis we observed a significant increase in the rate of drug consumption, which doubled from 157.8 DDDs/100 bed-days to 318.5 DDDs/100 bed-days. These figures are much higher than the 108.5 DDDs/ 12 antimicrobial consumption varied greatly, from 84 to 428 DDDs/100 bed-days, with a median consumption of 112 DDDs/100 bed-days. One limitation in the measurement of antibiotic consumption in DDDs/100 bed-days is its inability to adjust antibiotic use according to variations in the case mix over time. The high antibiotic consumption rate in our hospital is possibly due to a higher case mix index (CMI). CMI is an economic parameter that is calculated using diagnosisrelated groups, a measure that is today routinely used in various countries as a basis for hospital reimbursement. 13 Kuster et al.
14 found a significant correlation between CMI and antibiotic use when calculated in DDDs/100 bed-days. They also showed that the antibiotic use varied from 21 in the rheumatology unit, with a lower CMI, to 323 DDD/100 patient-days in the transplantation unit, with a higher CMI. 14 Since Sir Ganga Ram Hospital is an active centre for liver, renal and bone narrow transplant surgeries, it is possible that the increase in antibiotic consumption is related more to the higher CMI in our hospital compared with other hospitals. The other reason for high consumption of antimicrobials in our setting may be because of high antimicrobial resistance and thus the tendency to treat infection with multiple antimicrobials. Also, Sir Ganga Ram Hospital, being a tertiary care referral centre, performs a large number of complicated referred surgeries. A total of 23 874 total surgeries performed in 2008 is a case in point. We have many post-surgical cases where there is a general tendency to prescribe multiple antimicrobials, often in the absence of microbiological data. No significant trends in antibiotic consumption were seen for aminoglycosides, thirdgeneration cephalosporins and fluoroquinolones. This reflects the emergence of MDR strains, and consequently fewer prescriptions of these first-line antibiotics. Since combination therapy of b-lactams and fluoroquinolones/aminoglycosides is recommended for treatment of nosocomial non-fermenters, 15 the increasing prevalence of MDR in non-fermenters has led to a switch to second-line antibiotics, such as b-lactam/inhibitor combinations and carbapenems, in our hospital, which is also reflected in the significant increase in the consumption of these antimicrobials. Similar trends of third-generation cephalosporins, b-lactam/inhibitor combinations and carbapenems were also seen in a 10 year (1997 -2007) MYSTIC surveillance programme. 16 Although increasing consumption trends for b-lactam/inhibitor combinations and carbapenems were not reported in surveillance studies by other authors, 17, 18 this was probably due to their short study period or restrictions on antibiotic prescriptions during the study period, which was not the case in our study.
The increasing trend in resistance to fluoroquinolones, b-lactam/inhibitor combinations and aminoglycosides among non-fermenters may have been the result of high fluoroquinolone consumption until 2005, as this is known to be a risk factor in the emergence of MDR bacteria. 17 Although fluoroquinolone use declined after 2005, the increased use of broadspectrum antibiotics, b-lactam/inhibitor combinations and carbapenems contributed to the emergence of MDR strains.
Our results show there was rapid emergence of carbapenem resistance in A. baumannii compared with P. aeruginosa. Similar trends of resistance in non-fermenters causing bacteraemia among non-fermenters were observed by Livermore et al. , but the number of isolates was relatively small in this study. Resistance rates of 3%-82% to aminoglycosides, 19%-74% to fluoroquinolones, 8% to 34% to b-lactam/inhibitor combinations and 17%-74% to carbapenems among nonfermenters have been reported worldwide, 4,10,17 -20 indicating wide variation worldwide. Scarce published literature from Southeast Asia also show a high prevalence of carbapenem resistance (36%-90%) among non-fermenters. 21, 22 Additionally, to analyse the cause of carbapenem resistance among non-fermenters in 2008, we performed phenotypic testing for metallo-b-lactamase (MBL) by Etest MBL strips 23 on 50 consecutive blood isolates each of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii. Although MBLs in P. aeruginosa are the common cause of carbapenem hydrolysis, 24 OXA carbapenemases are considered more common in A. baumannii. 19 In contrast, we observed that MBLs were the main mechanism of carbapenem resistance in both P. aeruginosa (92.8%) and A. baumannii (88%). Similar emergence of MBLs as a prominent cause of carbapenem resistance (24.5%) was seen in Enterobacteriaceae in our hospital, which was 35.8% in 2008. Recently there have been reports of the emergence and rapid spread of a novel MBL designated as New Delhi MBL-1 (NDM-1) in Indian hospitals. 25 This increase in MBLs in Enterobacteriaceae can also be explained by the rapid spread of NDM-1 in our hospital, as few of our MBL-producing isolates screened for NDM-1 were positive by PCR. As A. baumannii isolates in Indian hospitals have also been found to carry NDM-1 carbapenemase genes giving very broad-spectrum antibiotic resistance profiles, 26 we fear that the emergence of MBLs in A. baumannii is due to NDM-1, although this needs to be confirmed by a genotypic method. As more than 70% of non-fermenters in our hospital are resistant to all antimicrobials, carbapenems and colistin are often administered presumptively in the treatment of suspected bacteraemia among critically ill patients. Even after the availability of susceptibility reports, colistin remains the only therapeutic option in the majority of our patients, although high-quality pharmacokinetic data and clinical outcome studies are lacking for polymyxin therapy. 27 Tigecycline, introduced in 2006 in our hospital for MDR bacteria, is already showing resistance of up to 70% among Goel et al.
A. baumannii isolates in ICUs. These trends worldwide indicate that carbapenem-resistant A. baumannii is emerging as a major nosocomial pathogen. Although MDR Acinetobacter infections are of low virulence, they are associated with high crude mortality rates (26%-68%) 28 -30 since they usually occur in critically ill patients in ICUs with few therapeutic options.
There are varying reports in the literature both supporting and refuting the relationships between antibiotic consumption and resistance, 4, 17, 18 suggesting local factors play an important role in such relationships. In our study we did not observe any association between antimicrobial consumption and development of resistance except for a weak association for carbapenems in A. baumannii ( Table 2 ). The reason for the lack of correlation observed may be explained by the fact that resistance to one antibiotic is associated with cross-resistance to other antimicrobials. 17 Lepper et al. 18 demonstrated in their study that imipenem therapy was associated with resistance to piperacillin/ tazobactam and ceftazidime in P. aeruginosa, whereas Messadi et al. 17 showed a significant correlation between ciprofloxacin consumption and resistance to imipenem (r ¼0.89, P ¼ 0.043) in P. aeruginosa. Further imipenem resistance being integron borne imparts co-resistance to other antibiotics resulting in MDR organisms containing MDR gene cassettes. 20 Therefore, in institutions where there is high carbapenem consumption and resistance, it predisposes to cross-resistance to all classes of drugs and thus masks the effects of antibiotic use and resistance for other classes of drugs, as also seen in our study.
We observed that the development of carbapenem resistance in A. baumannii was associated with carbapenem use (Figure 2) , which is in accordance with other studies. 4, 17 The weak association (P ¼ 0.049) may be explained by the fact that, other than for antimicrobial use, horizontal spread of A. baumannii because of its extended survival time has been shown to result in persistence and spread of endemic MDRAB infections in healthcare centres. 27 These two reasons may also explain the preferential emergence of MDRAB over MDRPA during the 10 years of our study period. In addition, importation of de novo MDR bacteria from other institutes and their maintenance in susceptible hosts may also be contributing to the emergence of carbapenem-resistant non-fermenters in our hospital. To that end, we often receive critical patients from other hospitals in whom carbapenem-resistant non-fermenters are isolated within 48 h of admission.
Since the results of our study show alarming trends of increasing resistance and antimicrobial use, which greatly threaten the utility of our existing antimicrobial armamentarium, immediate remedial actions need to be implemented to salvage the situation. Although we have an active hospital infection committee and an antibiotic policy in place, more innovative measures need to be explored. Towards that aim, we are undertaking an intervention initiative where doctors get monthly feedback of their qualitative and quantitative antimicrobial prescriptions compared with their peer group and other specialties, as well as a monthly update on hospital antibiogram and antibiotic policy, to observe if this continuous feedback results in increased compliance to hospital antibiotic policy and more prudent use of antimicrobials. Restricted use of last-resort antibiotics, like imipenem, by written approval from an infectious disease specialist or by a computer approval system have also shown to result in an improved rate of appropriate empirical antibiotic treatment and reduction in antibiotic treatment costs. 18, 31 Enhanced environmental cleaning and improved hand hygiene are practical and effective measures to prevent the horizontal spread of non-fermenters. 27 Special dedicated staffing and physical separation of high antibiotic use areas, such as oncology and liver transplant units from cardiology or medicine units, can be explored in referral hospitals like ours. This policy is currently being implemented for a paediatric ICU in our hospital with encouraging preliminary results.
We would like to address a few limitations of our study. Establishing an aetiological relationship between the rate of antimicrobial consumption and the prevalence of resistance may require other types of complex methodology with more timepoints. 32 Our study, with yearly aggregation of timepoints, may not be sensitive enough to reflect subtle changes in the complex interaction between antimicrobial drug prescribing and resistance. Furthermore, as this study was retrospective and uncontrolled in nature, potential confounders such as changes in the length of stay and case matching, staffing level and hand-hygiene compliance could not be factored while observing the trends. We also could not perform genotyping on the isolates to ascertain the clonality to help in interventional policies. 33 In conclusion, the results of this trend analysis are important, as this is the first of its kind from India documenting the trends of non-fermenters in bacteraemia over 10 years on a large number of isolates. Our study highlights the problems of high rates of antimicrobial consumption and the emergence of MDRAB due to carbapenem consumption as a prominent cause of bacteraemia. More studies are needed from other parts of India to determine the magnitude of the problem and formulate infection control guidelines relevant to our region.
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